Dr. Jonasch on Utilizing the Tumor Microenvironment and Epigenetics as Biomarkers in RCC

Video

In Partnership With:

Eric Jonasch, MD, on how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma.

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma (RCC).

The tumor microenvironment is made of up cells that yield signals, Jonasch explains. These signals, which may be associated with the genomics of the tumor, have the potential to inform clinicians on prognosis or specific treatment approaches.

Gene mutations are already known to be prognostic, Jonasch says. In RCC, a PBMR1 mutation is associated with a better outcome, whereas a worse outcome is associated with a BAP1 mutation, he says.

In the next 5 to 10 years, focus should be on understanding the role of the tumor microenvironment and of epigenetics as predictive biomarkers to develop more personalized therapies.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD